Tavi valve vs surgery for severe aortic regurgitation
Part of Heart & circulation clinical trials.
This trial compares a new catheter-based valve (J-Valve) with open-heart surgery for people with severe aortic regurgitation, a condition where the aortic valve doesn't close tightly. It aims to see which treatment is safer and more effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 65 years or older.
- You have severe aortic regurgitation and either have symptoms or signs that your heart is struggling (like a weak pump or enlarged heart).
- You are healthy enough for both surgery and the catheter procedure, as judged by a team of heart specialists.
- You do not have other serious heart valve problems or certain anatomical issues that would make the procedure unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new device to fix a leaky aortic valve in people who already have a mechanical heart pump (LVAD). The goal is to help the pump work better and reduce symptoms.
This trial compares a new less-invasive valve replacement (Trilogy TAVR) with standard open-heart surgery for people with significant aortic regurgitation. It aims to see which treatment works better for patients who are eligible for both procedures.
This study is testing a new, less invasive heart valve system (TaurusTrio) for people with severe aortic regurgitation (a leaky aortic valve) who cannot have open-heart surgery. It aims to see if the valve is safe and works well to improve symptoms.
This study tests a new valve replacement for people with severe aortic regurgitation (leaky heart valve) who are not good candidates for open surgery. The valve is put in through a small tube in the leg, which may be less risky for high-risk patients.
This trial studies a less invasive heart valve procedure that places a new valve through a catheter, to treat severe leakage of the aortic valve. It may help people who have symptoms or heart enlargement and who are at higher risk for open-heart surgery.
This trial studies people with severe aortic valve disease who will receive a catheter-based valve replacement (TAVR). It aims to check how well this approach works for fixing a narrowed or leaky aortic valve, and to monitor outcomes afterward.
Hear when a new Aortic Regurgitation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.